p21-activated kinase 1: PAK’ed with potential

Christy Ong; Adrian Jubb; Wei Zhou; Peter Haverty; Adrian Harris; Marcia Belvin; Lori Friedman; Hartmut Koeppen; Klaus Hoeflich

doi:10.18632/oncotarget.271

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

p21-activated kinase 1: PAK’ed with potential

Christy Ong, Adrian Jubb, Wei Zhou, Peter Haverty, Adrian Harris, Marcia Belvin, Lori Friedman, Hartmut Koeppen and Klaus Hoeflich _

PDF | HTML | How to cite

Oncotarget. 2011; 2:491-496. https://doi.org/10.18632/oncotarget.271

Metrics: PDF 4976 views | HTML 6145 views | ?

Abstract

Christy C. Ong^1,*, Adrian M. Jubb^2,*, Wei Zhou¹, Peter M. Haverty³, Adrian L. Harris², Marcia Belvin¹, Lori S. Friedman¹, Hartmut Koeppen⁴, Klaus P. Hoeflich^1,5

¹ Department of Translational Oncology, Genentech, Inc., South San Francisco, CA 94080, USA

² The Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford OX3 9DS, UK

³ Department of Bioinformatics, Genentech, Inc., South San Francisco, CA 94080, USA

⁴ Department of Pathology, Genentech, Inc., South San Francisco, CA 94080, USA

^* These authors contributed equally to this work.

Keywords: PAK1, apoptosis, squamous, lung cancer, breast cancer

Received: May 3, 2011; Accepted: June 2, 2011; Published: June 7, 2011;

Correspondence:

Klaus P. Hoeflich, e-mail:

Abstract

The p21-activated kinases (PAKs) are central players in growth factor signaling networks and morphogenetic processes that control proliferation, cell polarity, invasion and actin cytoskeleton organization. This raises the possibility that interfering with PAK activity may produce significant anti-tumor activity. In this perspective, we summarize recent data concerning the contribution of the PAK family member, PAK1, in growth factor signaling and tumorigenesis. We further discuss mechanisms by which inhibition of PAK1 can arrest tumor growth and promote cell apoptosis, and the types of cancers in which PAK1 inhibition may hold promise.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 271

Publication Alerts

Research Perspectives:

p21-activated kinase 1: PAK’ed with potential

Abstract